Going Concern Warning Reiterated with Short Cash Runway, Increased Losses, and Significant CEO Performance Grant Amidst Dilutive Debt Default

summarizeSummary

BIOXYTRAN, INC. reported worsening financials, a reiterated going concern warning with cash only until September 2026, and a significant non-cash performance grant to its CEO, alongside dilutive debt and internal control issues.

check_boxKey Events

• Going Concern Warning & Limited Cash Runway

  The company reiterated substantial doubt about its ability to continue as a going concern, with current cash of $463,047 sufficient only until September 2026. Management plans to raise $2-3 million but offers no assurance of success.

• Increased Net Loss and Cash Burn

  Net loss for Q1 2026 increased to $2.07 million from $1.35 million in Q1 2025. Net cash used in operating activities rose to $238,610 from $167,323 in the prior year period, indicating an accelerating cash burn.

• Significant Non-Cash CEO Performance Grant

  The CEO, Dr. Platt, received a non-cash performance grant of 6,000,000 Preferred Shares (equivalent to 30,000,000 common shares) valued at $1.28 million, representing a substantial compensation expense for a company in financial distress.

• Convertible Note in Default with Dilutive Terms

  A 2021 convertible note with a principal of $805,000 (total amount due $1.12 million including accrued interest) has been in default since March 1, 2025, carrying an 18% default interest rate and a highly dilutive price adjustment feature.

auto_awesomeAnalysis

This quarterly report highlights severe financial distress, with the company explicitly stating substantial doubt about its ability to continue as a going concern and a cash runway only until September 2026. The net loss and cash burn have significantly increased, and a convertible note remains in default with highly dilutive conversion terms. A substantial non-cash performance grant to the CEO, valued at $1.28 million (equivalent to 30 million common shares), is particularly concerning given the company's precarious financial state and small market capitalization. While some capital was raised through private placements, the amounts are insufficient to meet the stated funding needs, and material weaknesses in internal controls persist, further eroding investor confidence.